title: [Pleiotropic Effects of Rosuvastatin in Chronic Obstructive Pulmonary Disease Patients With High Cardiovascular Risk].
abstract: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the list of common causes of mortality after cardiovascular diseases. The processes of atherogenesis and cardiovascular diseases are accelerated in patients with COPD. The key mechanisms of COPD pathogenesis are oxidative stress, depletion of antioxidant protection, development of the pulmonary and systemic inflammation and the development of endothelial dysfunction. This article discusses the pleiotropic effects of statins in patients with COPD.
authors.forename: E I
authors.initials: EI
authors.lastname: Samorukova
authors.forename: T V
authors.initials: TV
authors.lastname: Adasheva
authors.forename: V S
authors.initials: VS
authors.lastname: Zadionchenko
authors.forename: G A
authors.initials: GA
authors.lastname: Rosliakova
mesh_terms: D002318:Cardiovascular Diseases / Q000150:complications / Q000453:epidemiology* / Q000378:metabolism / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D015994:Incidence; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D012189:Retrospective Studies; D012307:Risk Factors; D000068718:Rosuvastatin Calcium / Q000008:administration & dosage*; D012426:Russia / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000068718:Rosuvastatin Calcium